Mesenchymal stem cell therapy for treatment of cardiovascular disease: Helping people sooner or later

Stem Cells and Development

Volumn 19, Issue 7, 2010, Pages 1109-1120

  Trivedi, Premal ^a   Tray, Nancy ^a   Nguyen, Thuy ^a   Nigam, Neha ^a   Gallicano, G Ian ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 2; CD71 ANTIGEN; ESTROGEN RECEPTOR; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 4; HEME OXYGENASE 1; HERMES ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 4 RECEPTOR ALPHA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN SH2; PROTEIN SH3; SCATTER FACTOR; SMALL INTERFERING RNA; SOMATOMEDIN; SOMATOMEDIN C; STRESS ACTIVATED PROTEIN KINASE; STROMAL CELL DERIVED FACTOR 1; THY 1 ANTIGEN; TRANSFORMING GROWTH FACTOR ALPHA; TRIMETAZIDINE; TUMOR NECROSIS FACTOR RECEPTOR 1; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ACUTE HEART INFARCTION; ANGIOGENESIS; ANIMAL EXPERIMENT; APOPTOSIS; BONE MARROW; CARDIOVASCULAR FUNCTION; CELL ADHESION; CELL DIFFERENTIATION; CELL ISOLATION; CELL MIGRATION; CELL REGENERATION; CELL TRANSPLANTATION; CLINICAL EFFECTIVENESS; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DOWNSTREAM PROCESSING; ENGRAFTMENT; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HUMAN; HYPOXIA; IN VITRO STUDY; INJECTION; ISCHEMIA; ISCHEMIC HEART DISEASE; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MUSCLE DEVELOPMENT; NONHUMAN; PRIORITY JOURNAL; PURIFICATION; REPERFUSION INJURY; REVIEW; SCAR FORMATION; STROMA CELL; ANIMAL; CARDIOVASCULAR DISEASES; CLINICAL TRIAL (TOPIC); CYTOLOGY; HEART INFARCTION PREVENTION; HEART MUSCLE; MESENCHYMAL STROMA CELL; METABOLISM; PARACRINE SIGNALING; PATHOLOGY; PHYSIOLOGY; REGENERATION; STEM CELL TRANSPLANTATION;

ANIMALIA;

ANIMALS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; HUMANS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MYOCARDIUM; PARACRINE COMMUNICATION; REGENERATION; STEM CELL TRANSPLANTATION;

EID: 77954944580     PISSN: 15473287     EISSN: None     Source Type: Journal    
DOI: 10.1089/scd.2009.0465     Document Type: Review

References (55)

1. Psaltis PJ, AC Zannettino, SG Worthley and S Gronthos. (2008). Concise review: mesenchymal stromal cells: potential for cardiovascular repair. Stem Cells 26: 2201-2210.
2. Bianco P, M Riminucci, S Gronthos and PG Robey. (2001). Bone marrow stromal stem cells: nature, biology, and potential applications. Stem Cells 19: 180-192.
3. Gronthos S, M Mankani, J Brahim, PG Robey and S Shi. (2000). Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo. Proc Natl Acad Sci USA 97: 13625-13630.
4. Seo BM, M Miura, S Gronthos, PM Bartold, S Batouli, J Brahim, M Young, PG Robey, CY Wang and S Shi. (2004). Investigation of multipotent postnatal stem cells from human periodontal ligament. Lancet 364: 149-155.
5. Shi S and S Gronthos. (2003). Perivascular niche of postnatal mesenchymal stem cells in human bone marrow and dental pulp. J Bone Miner Res 18: 696-704.
6. Beltrami AP, L Barlucchi, D Torella, M Baker, F Limana, S Chimenti, H Kasahara, M Rota, E Musso, K Urbanek, A Leri, J Kajstura, B Nadal-Ginard and P Anversa. (2003). Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 114: 763-776.
7. Jiang S, H Kh Haider, RP Ahmed, NM Idris, A Salim and M Ashraf. (2008). Transcriptional profiling of young and old mesenchymal stem cells in response to oxygen deprivation and reparability of the infarcted myocardium. J Mol Cell Cardiol 44: 582-596.
8. Ryan JM, FP Barry, JM Murphy and BP Mahon. (2005). Mesenchymal stem cells avoid allogeneic rejection. J Inflamm (Lond) 2: 8.
9. Oswald J, S Boxberger, B Jørgensen, S Feldmann, G Ehninger, M Bornhäuser and C Werner. (2004). Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells 22: 377-384.
10. Pittenger MF, AM Mackay, SC Beck, RK Jaiswal, R Douglas, JD Mosca, MA Moorman, DW Simonetti, S Craig and DR Marshak. (1999). Multilineage potential of adult human mesenchymal stem cells. Science 284: 143-147.
11. Friedenstein AJ, RK Chailakhjan and KS Lalykina. (1970). The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet 3: 393-403.
12. Shim WS, S Jiang, P Wong, J Tan, YL Chua, YS Tan, YK Sin, CH Lim, T Chua, M Teh, TC Liu and E Sim. (2004). Ex vivo differentiation of human adult bone marrow stem cells into cardiomyocyte-like cells. Biochem Biophys Res Commun 324: 481-488.
13. Yoon J, BG Min, YH Kim, WJ Shim, YM Ro and DS Lim. (2005). Differentiation, engraftment and functional effects of pretreated mesenchymal stem cells in a rat myocardial infarct model. Acta Cardiol 60: 277-284.
14. Behfar A, RS Faustino, DK Arrell, PP Dzeja, C Perez-Terzic and A Terzic. (2008). Guided stem cell cardiopoiesis: discovery and translation. J Mol Cell Cardiol 45: 523-529.
15. Rangappa S, JW Entwistle, AS Wechsler and JY Kresh. (2003). Cardiomyocyte-mediated contact programs human mesenchymal stem cells to express cardiogenic phenotype. J Thorac Cardiovasc Surg 126: 124-132.
16. Toma C, MF Pittenger, KS Cahill, BJ Byrne and PD Kessler. (2002). Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 105: 93-98.
17. Amado LC, AP Saliaris, KH Schuleri, M St John, JS Xie, S Cattaneo, DJ Durand, T Fitton, JQ Kuang, G Stewart, S Lehrke, WW Baumgartner, BJ Martin, AW Heldman and JM Hare. (2005). Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proc Natl Acad Sci USA 102: 11474-11479.
18. Valina C, K Pinkernell, YH Song, X Bai, S Sadat, RJ Campeau, TH Le Jemtel and E Alt. (2007). Intracoronary administration of autologous adipose tissue-derived stem cells improves left ventricular function, perfusion, and remodelling after acute myocardial infarction. Eur Heart J 28: 2667-2677.
19. Silva GV, S Litovsky, JA Assad, AL Sousa, BJ Martin, D Vela, SC Coulter, J Lin, J Ober, WK Vaughn, RV Branco, EM Oliveira, R He, YJ Geng, JT Willerson and EC Perin. (2005). Mesenchymal stem cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a canine chronic ischemia model. Circulation 111: 150-156.
20. Schuleri KH, GS Feigenbaum, M Centola, ES Weiss, JM Zimmet, J Turney, J Kellner, MM Zviman, KE Hatzistergos, B Detrick, JV Conte, I McNiece, C Steenbergen, AC Lardo and JM Hare. (2009). Autologous mesenchymal stem cells produce reverse remodelling in chronic ischaemic cardiomyopathy. Eur Heart J 30: 2722-2732.
21. Nagaya N, K Kangawa, T Itoh, T Iwase, S Murakami, Y Miyahara, T Fujii, M Uematsu, H Ohgushi, M Yamagishi, T Tokudome, H Mori, K Miyatake and S Kitamura. (2005). Transplantation of mesenchymal stem cells improves cardiac function in a rat model of dilated cardiomyopathy. Circulation 112: 1128-1135.
22. Ohnishi S, B Yanagawa, K Tanaka, Y Miyahara, H Obata, M Kataoka, M Kodama, H Ishibashi-Ueda, K Kangawa, S Kitamura and N Nagaya. (2007). Transplantation of mesenchymal stem cells attenuates myocardial injury and dysfunction in a rat model of acute myocarditis. J Mol Cell Cardiol 42: 88-97.
23. Plotnikov AN, I Shlapakova, MJ Szabolcs, P Danilo Jr, BH Lorell, IA Potapova, Z Lu, AB Rosen, RT Mathias, PR Brink, RB Robinson, IS Cohen and MR Rosen. (2007). Xenografted adult human mesenchymal stem cells provide a platform for sustained biological pacemaker function in canine heart. Circulation 116: 706-713.
24. Vincentelli A, F Wautot, F Juthier, O Fouquet, D Corseaux, S Marechaux, T Le Tourneau, O Fabre, S Susen, E Van Belle, F Mouquet, C Decoene, A Prat and B Jude. (2007). In vivo autologous recellularization of a tissue-engineered heart valve: are bone marrow mesenchymal stem cells the best candidates? J Thorac Cardiovasc Surg 134: 424-432.
25. Breitbach M, T Bostani, W Roell, Y Xia, O Dewald, JM Nygren, JW Fries, K Tiemann, H Bohlen, J Hescheler, A Welz, W Bloch, SE Jacobsen and BK Fleischmann. (2007). Potential risks of bone marrow cell transplantation into infarcted hearts. Blood 110: 1362-1369.
26. Price MJ, CC Chou, M Frantzen, T Miyamoto, S Kar, S Lee, PK Shah, BJ Martin, M Lill, JS Forrester, PS Chen and RR Makkar. (2006). Intravenous mesenchymal stem cell therapy early after reperfused acute myocardial infarction improves left ventricular function and alters electrophysiologic properties. Int J Cardiol 111: 231-239
27. Anonymous Investor Relations/Osiris Reports Positive Two-Year Data on Stem Cell Treatment for Acute Myocardial Infarction, 2010. URL: http://investor.osiris.com/releasedetail. cfm?ReleaseID=364825.
28. Bartunek J, W Sherman, M Vanderheyden, F Fernandez-Aviles, W Wijns and A Terzic. (2009). Delivery of biologics in cardiovascular regenerative medicine. Clin Pharmacol Ther 85: 548-552.
29. Janssens S, C Dubois, J Bogaert, K Theunissen, C Deroose, W Desmet, M Kalantzi, L Herbots, P Sinnaeve, J Dens, J Maertens, F Rademakers, S Dymarkowski, O Gheysens, J Van Cleemput, G Bormans, J Nuyts, A Belmans, L Mortelmans, M Boogaerts and F Van de Werf. (2006). Autologous bone marrow-derived stemcell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet 367: 113-121.
30. Furlani D, M Ugurlucan, L Ong, K Bieback, E Pittermann, I Westien, W Wang, C Yerebakan, W Li, R Gaebel, RK Li, B Vollmar, G Steinhoff and N Ma. (2009). Is the intravascular administration of mesenchymal stem cells safe? Mesenchymal stem cells and intravital microscopy. Microvasc Res 77: 370-376.
31. Toma C, WR Wagner, S Bowry, A Schwartz and F Villanueva. (2009). Fate of culture-expanded mesenchymal stem cells in the microvasculature: in vivo observations of cell kinetics. Circ Res 104: 398-402.
32. Perin EC, GV Silva, JA Assad, D Vela, LM Buja, AL Sousa, S Litovsky, J Lin, WK Vaughn, S Coulter, MR Fernandes and JT Willerson. (2008). Comparison of intracoronary and transendocardial delivery of allogeneic mesenchymal cells in a canine model of acute myocardial infarction. J Mol Cell Cardiol 44: 486-495.
33. Freyman T, G Polin, H Osman, J Crary, M Lu, L Cheng, M Palasis and RL Wilensky. (2006). A quantitative, randomized study evaluating three methods of mesenchymal stem cell delivery following myocardial infarction. Eur Heart J 27: 1114-1122.
34. Gnecchi M, H He, N Noiseux, OD Liang, L Zhang, F Morello, H Mu, LG Melo, RE Pratt, JS Ingwall and VJ Dzau. (2006). Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J 20: 661-669.
35. Gnecchi M, Z Zhang, A Ni and VJ Dzav. (2008). Paracrine mechanisms in adult stem cell signaling and theraphy. Circ Res 103:1204-1219.
36. Cheng AS and TM Yau. (2008). Paracrine effects of cell transplantation: strategies to augment the efficacy of cell therapies. Semin Thorac Cardiovasc Surg 20: 94-101.
37. Markel TA, Y Wang, JL Herrmann, PR Crisostomo, M Wang, NM Novotny, CM Herring, J Tan, T Lahm and DR Meldrum. (2008). VEGF is critical for stem cell-mediated cardioprotection and a crucial paracrine factor for defining the age threshold in adult and neonatal stem cell function. Am J Physiol Heart Circ Physiol 295: H2308-H2314.
38. Crisostomo PR, Y Wang, TA Markel, M Wang, T Lahm and DR Meldrum. (2008). Human mesenchymal stem cells stimulated by TNF-alpha, LPS, or hypoxia produce growth factors by an NF kappa B-but not JNK-dependent mechanism. Am J Physiol, Cell Physiol 294: C675-C682.
39. Shi RZ, JC Wang, SH Huang, XJ Wang and QP Li. (2009). Angiotensin II induces vascular endothelial growth factor synthesis in mesenchymal stem cells. Exp Cell Res 315: 10-15.
40. Yun SP, MY Lee, JM Ryu, CH Song and HJ Han. (2009). Role of HIF-1alpha and VEGF in human mesenchymal stem cell proliferation by 17beta-estradiol: involvement of PKC, PI3K/Akt, and MAPKs. Am J Physiol, Cell Physiol 296: C317-C326.
41. Balsam LB, AJ Wagers, JL Christensen, T Kofidis, IL Weissman and RC Robbins. (2004). Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. Nature 428: 668-673.
42. Nakamura Y, X Wang, C Xu, A Asakura, M Yoshiyama, AH From and J Zhang. (2007). Xenotransplantation of long-termcultured swine bone marrow-derived mesenchymal stem cells. Stem Cells 25: 612-620.
43. Noiseux N, M Gnecchi, M Lopez-Ilasaca, L Zhang, SD Solomon, A Deb, VJ Dzau and RE Pratt. (2006). Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation. Mol Ther 14: 840-850.
44. Norol F, N Bonnet, A Peinnequin, F Chretien, R Legrand, R Isnard, F Herodin, C Baillou, B Delache, D Negre, D Klatzmann, JP Vernant and FM Lemoine. (2007). GFP-transduced CD34+ and Lin-CD34-hematopoietic stem cells did not adopt a cardiac phenotype in a nonhuman primate model of myocardial infarct. Exp Hematol 35: 653-661.
45. Li W, N Ma, LL Ong, C Nesselmann, C Klopsch, Y Ladilov, D Furlani, C Piechaczek, JM Moebius, K Lützow, A Lendlein, C Stamm, RK Li and G Steinhoff. (2007). Bcl-2 engineered MSCs inhibited apoptosis and improved heart function. Stem Cells 25: 2118-2127.
46. Zhang M, N Mal, M Kiedrowski, M Chacko, AT Askari, ZB Popovic, ON Koc and MS Penn. (2007). SDF-1 expression by mesenchymal stem cells results in trophic support of cardiac myocytes after myocardial infarction. FASEB J 21: 3197-3207.
47. Guo J, G Lin, C Bao, Z Hu, H Chu and M Hu. (2008). Insulinlike growth factor 1 improves the efficacy of mesenchymal stem cells transplantation in a rat model of myocardial infarction. J Biomed Sci 15: 89-97.
48. Pons J, Y Huang, J Arakawa-Hoyt, D Washko, J Takagawa, J Ye, W Grossman and H Su. (2008). VEGF improves survival of mesenchymal stem cells in infarcted hearts. Biochem Biophys Res Commun 376: 419-422.
49. Herrmann JL, Y Wang, AM Abarbanell, BR Weil, J Tan and DR Meldrum. (2010). Preconditioning mesenchymal stem cells with transforming growth factor alpha improves mesenchymal stem cell-mediated cardio protein. Shock 33:24-30.
50. Wisel S, M Khan, ML Kuppusamy, IK Mohan, SM Chacko, BK Rivera, BC Sun, K Hideg and P Kuppusamy. (2009). Pharmacological preconditioning of mesenchymal stem cells with trimetazidine (1-[2,3,4-trimethoxybenzyl]piperazine) protects hypoxic cells against oxidative stress and enhances recovery of myocardial function in infarcted heart through Bcl-2 expression. J Pharmacol Exp Ther 329: 543-550.
51. Zeng B, X Ren, G Lin, C Zhu, H Chen, J Yin, H Jiang, B Yang and D Ding. (2008). Paracrine action of HO-1-modified mesenchymal stem cells mediates cardiac protection and functional improvement. Cell Biol Int 32: 1256-1264.
52. Hahn JY, HJ Cho, HJ Kang, TS Kim, MH Kim, JH Chung, JW Bae, BH Oh, YB Park and HS Kim. (2008). Pre-treatment of mesenchymal stem cells with a combination of growth factors enhances gap junction formation, cytoprotective effect on cardiomyocytes, and therapeutic efficacy for myocardial infarction. J Am Coll Cardiol 51: 933-943.
53. Garcia-Fuentes M, AJ Meinel, M Hilbe, L Meinel and HP Merkle. (2009). Silk fibroin/hyaluronan scaffolds for human mesenchymal stem cell culture in tissue engineering. Biomaterials 30: 5068-5076.
54. Hu BH, J Su and PB Messersmith. (2009). Hydrogels cross-linked by native chemical ligation. Biomacromolecules 10: 2194-2200.
55. Jin J, SI Jeong, YM Shin, KS Lim, H Shin, YM Lee, HC Koh and KS Kim. (2009). Transplantation of mesenchymal stem cells within a poly(lactide-co- epsilon-caprolactone) scaffold improves cardiac function in a rat myocardial infarction model. Eur J Heart Fail 11: 147-153.